SPDR S&P BIOTECH ETF (XBI)
| Assets | $6.04B |
| Expense Ratio | 0.35% |
| PE Ratio | n/a |
| Shares Out | n/a |
| Dividend (ttm) | $0.00 |
| Dividend Yield | 0.00% |
| Ex-Dividend Date | Jun 20, 2023 |
| Payout Ratio | n/a |
| 1-Year Return | -6.57% |
| Volume | 9,650,909 |
| Open | 73.95 |
| Previous Close | 73.70 |
| Day's Range | 72.81 - 74.22 |
| 52-Week Low | 72.44 |
| 52-Week High | 92.60 |
| Beta | n/a |
| Holdings | 138 |
| Inception Date | Jan 31, 2006 |
About XBI
Fund Home PageThe SPDR S&P BIOTECH ETF (XBI) is an exchange-traded fund that is based on the S&P Biotechnology Select Industry index. The fund tracks an equal-weighted index of US biotechnology stocks. XBI was launched on Jan 31, 2006 and is issued by State Street.
Top 10 Holdings
13.35% of assets| Name | Symbol | Weight |
|---|---|---|
| Apellis Pharmaceuticals, Inc. | APLS | 1.45% |
| Amgen Inc. | AMGN | 1.33% |
| Halozyme Therapeutics, Inc. | HALO | 1.33% |
| Neurocrine Biosciences, Inc. | NBIX | 1.33% |
| Vertex Pharmaceuticals Incorporated | VRTX | 1.33% |
| Ionis Pharmaceuticals, Inc. | IONS | 1.32% |
| Alkermes plc | ALKS | 1.32% |
| AbbVie Inc. | ABBV | 1.32% |
| Mirati Therapeutics, Inc. | MRTX | 1.31% |
| Seagen Inc. | SGEN | 1.30% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| 2023-06-20 | $0.00262 | 2023-06-23 |
| 2021-03-22 | $0.040 | 2021-03-25 |
| 2020-12-21 | $0.176 | 2020-12-24 |
| 2020-09-21 | $0.08897 | 2020-09-24 |
| 2020-06-22 | $0.01676 | 2020-06-25 |
| 2019-12-20 | $0.00086 | 2019-12-26 |
News
ETF flows point to ‘skittish' investors as it's ‘a little unwieldy out there' after Fed rate hikes
Hello! In this week's ETF Wrap, I caught up with The ETF Store's Nate Geraci and State Street's Matthew Bartolini on flows as investors worry about a potential recession and try to discern the Fed's n...
Biotech ETFs' Performance Deserves A Look
Biotech comes with a great many positive externalities for society, and can be a big positive for portfolios right now.
How to Tell Biotech's Likely Winners From Losers
A discerning approach is warranted even as Merck lifts the sector with a deal for a company without any approved products.
Final Trades: XBI, BXP, SPY & MRK
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
The FDA Is Resuming Drug Lab Inspections in China. These Biotechs Could Benefit.
China's pandemic-era travel restrictions paused approvals on some new drugs. The end of Zero Covid means the pipeline will reopen.
Final Trades: Biotech, Defense, Thermo Fisher & more
The "Halftime Report" traders give their top picks to watch for the second half.
Passive Funds' Ownership of US Stocks Soars
Share prices appear unaffected as passive ETF and mutual fund stakes hit 19%, analysis says.
Regional banks pace decliners, as biotech deals lift Seagen and Provention Bio
Here are some of the biggest movers on Monday with banks firmly in focus after federal regulators stepped into protect deposits at fallen bank SVB.
SVB fallout: The impacts on the biotech sector
CNBC's Meg Tirrell reports on how the SVB fallout could impact biotech investors.
Biotech ETF nears a six-month low
Shares of the SPDR S&P Biotech ETF XBI tumbled toward a six-month low last week, closing at $75.66 on Friday, over concerns about biotech exposure to Silicon Valley Bank, which is owned by SVB Financi...
The Recent Bullish Trend in IBB, XBI Looks Shaky
Rising interest rates taking steam from rally that powered in IBB and XBI.
Analysis: Biotech IPOs to bloom with spotlight on startups with human trial data
Initial public offerings by small private biotech companies are poised to stage a comeback later in 2023 as the pace of interest rate hikes slows, but tougher economic conditions will make investors m...
There's a crop of great biotech companies ready to be acquired, says MPM's Christiana Bardon
Dr. Christiana Bardon, co-managing partner of MPM's BioImpact Capital, joins 'The Exchange' to discuss tailwinds in the pharmaceutical and biotech sector, innovation in obesity drugs, and acquisition ...
Final Trades: Stryker, DaVita, Biotech and more
The "Halftime Report" traders give their top picks to watch for the second half.
Why Biotech Is Poised for a Recovery This Year
Pharma and biotech stocks moved in opposite directions last year, but fortunes are shifting.
Will 2023 be the year that pharma M&A makes a comeback?
A handful of acquisitions this week point to a more deal-friendly year for biopharma and biotech companies, though none has generated the kind of excitement seen in years past.
Expect heavy market selling early next year, says Worth Charting's Carter Worth
Carter Worth, Worth Charting CEO, joins 'The Exchange' to give the technical take on Eli Lilly and XBI.
Final Trades: ServiceNow, Devon Energy S&P Biotech & more
The "Halftime Report" traders give their top picks to watch for the second half.
XBI vs IBB: what's a better way to play the biotech space?
Biotech will continue to outperform the benchmark since the U.S. economy is currently in late-cycle expansion, says Bryn Talkington. She's a Managing Partner at Requisite Capital Management.
Requisite's Bryn Talkington discusses whys she liked XBI over IBB in biotech
Bryn Talkington, Requisite Capital, joins 'Closing Bell: Overtime' to discuss the biotech sector.
Janney Montgomery Scott's Mark Luschini urges near-term caution
Mark Luschini, Janney Montgomery Scott chief investment strategist, joins 'Power Lunch' to discuss September's Fed minutes, cautious sectors to invest in, and forces influencing defensive stock prices...
Life sciences is undervalued right now, says JMP Securities Mark Lehmann
JMP Securities CEO Mark Lehmann joins 'Closing Bell: Overtime' to discuss why he likes health care stocks as the place to be right now.
White House unveils $2 billion biotech spending plan ahead of industry summit
The White House released new details on Wednesday on how it plans to invest more than $2 billion in the U.S. biotechnology sector as it hosts a meeting of government leaders to discuss the emerging in...